(Q30778435)

14 October 2017

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? (English)

1 reference

14 October 2017

Kiyomi Ito

1

1 reference

14 October 2017

Koji Chiba

2

1 reference

14 October 2017

Masato Horikawa

3

1 reference

14 October 2017

Michi Ishigami

4

1 reference

14 October 2017

Naomi Mizuno

5

1 reference

14 October 2017

Jun Aoki

6

1 reference

14 October 2017

Yasumasa Gotoh

7

1 reference

14 October 2017

Takafumi Iwatsubo

8

1 reference

14 October 2017

Shin-ichi Kanamitsu

9

1 reference

14 October 2017

Motohiro Kato

10

1 reference

14 October 2017

Iichiro Kawahara

11

1 reference

14 October 2017

Kayoko Niinuma

12

1 reference

14 October 2017

Akiko Nishino

13

1 reference

14 October 2017

Norihito Sato

14

1 reference

14 October 2017

Yuko Tsukamoto

15

1 reference

14 October 2017

Kaoru Ueda

16

1 reference

14 October 2017

Tomoo Itoh

17

1 reference

14 October 2017

Yuichi Sugiyama

18

1 reference

14 October 2017

1 January 2002

1 reference

14 October 2017

1 reference

14 October 2017

4

1 reference

14 October 2017

4

1 reference

14 October 2017

E25

1 reference

Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Protease inhibitors for the treatment of human immunodeficiency virus infection

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Clinical pharmacokinetics of nefazodone

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Effect of fluconazole dose on the extent of fluconazole-triazolam interaction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Stereoselective interaction between piroxicam and acenocoumarol

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

The safety profile of nefazodone

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Newer antidepressants and the cytochrome P450 system

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Dangerous interaction between amiodarone and quinidine

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Ciprofloxacin increases serum levels of theophylline

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Diazepam and methadone blood levels following concurrent administration of diazepam and methadone.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Potent Inhibition of Cytochrome P450IID6 (Debrisoquin 4-Hydroxylase) by Flecainide In Vitro and In Vivo

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Effect of venlafaxine on the pharmacokinetics of alprazolam.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients

25 November 2018

1 reference

12 December 2020

Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine

1 reference

12 December 2020

The warfarin-sulfinpyrazone interaction: stereochemical considerations

1 reference

12 December 2020

Mexiletine and caffeine elimination

1 reference

12 December 2020

Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients

1 reference

12 December 2020

Interaction between propranolol and propafenone in healthy volunteers

1 reference

12 December 2020

Cyclosporine--high-dose steroid interaction in renal transplant recipients: assessment by HPLC

1 reference

12 December 2020

Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients

1 reference

12 December 2020

Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans

1 reference

12 December 2020

Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects

1 reference

12 December 2020

Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects

1 reference

12 December 2020

Lack of interaction between fluvastatin andoral nypoylycemie agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*

1 reference

12 December 2020

Pharmacokinetic interactions of nifedipine and quinidine

1 reference

12 December 2020

Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole

1 reference

12 December 2020

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies

1 reference

12 December 2020

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

1 reference

12 December 2020

Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients

1 reference

12 December 2020

Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver

1 reference

12 December 2020

Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo

1 reference

12 December 2020

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

12 December 2020

Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone

1 reference

12 December 2020

Effects of cimetidine and ranitidine on hepatic drug metabolism

1 reference

12 December 2020

Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects

1 reference

12 December 2020

Identifiers

DOI

10.1208/PS040425

1 reference

release_54diz32d7bc2hnlylax5qc4hf4

14 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/54diz32d7bc2hnlylax5qc4hf4

24 November 2022

mapped directly with Wikidata item

1 reference

14 October 2017

PubMed publication ID

12645997

1 reference